Jessica Valentina Umar, . (2026) HUBUNGAN DURASI TERAPI ANTIRETROVIRAL DENGAN KADAR CD4⁺ PADA PASIEN ODHA KOINFEKSI TB PARU DI RS IHC PELNI PERIODE 2023-2025. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
![[img]](http://repository.upnvj.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (211kB) |
|
Text
AWAL.pdf Download (1MB) |
|
Text
BAB 1.pdf Restricted to Repository UPNVJ Only Download (357kB) |
|
Text
BAB 2.pdf Restricted to Repository UPNVJ Only Download (1MB) |
|
Text
BAB 3.pdf Restricted to Repository UPNVJ Only Download (370kB) |
|
Text
BAB 4.pdf Restricted to Repository UPNVJ Only Download (1MB) |
|
Text
BAB 5.pdf Download (299kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (300kB) |
|
Text
RIWAYAT HIDUP.pdf Restricted to Repository staff only Download (105kB) |
|
Text
HASIL PLAGIARISME.pdf Restricted to Repository staff only Download (3MB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (1MB) |
|
Text
ARTIKEL KI.pdf Restricted to Repository staff only Download (589kB) |
Abstract
Introduction: The effectiveness of antiretroviral (ARV) therapy in people living with HIV/AIDS (PLWHA) is influenced by therapy duration and baseline immune status, with CD4⁺ count as the primary indicator. The relationship between ARV therapy duration and CD4⁺ improvement in PLWHA with pulmonary tuberculosis (TB) coinfection has been inconsistent. This study aimed to assess the sociodemographic and clinical characteristics of patients, CD4⁺ counts before and after ARV therapy, and the relationship between ARV therapy duration and CD4⁺ counts at IHC Pelni Hospital during 2023–2025. Methods: This study employed a retrospective quantitative observational approach with a cross-sectional design. Researchers obtained data from the medical records of patients who received first-line antiretroviral (ARV) therapy using the TLD regimen (TDF + 3TC + DTG, plus DTG 50 mg) and had documented CD4⁺ counts and tuberculosis coinfection status. The study used consecutive sampling to include 49 adult PLWHA with pulmonary TB coinfection. The researchers evaluated CD4⁺ counts before therapy and at 6 and 12 months after ARV therapy. Data analysis included univariate analysis, the Shapiro–Wilk normality test, the Wilcoxon test, and Spearman's Rho correlation analysis. Results: Most patients were aged 25–49 years (71.4%), male (83.7%), had high school or equivalent education (79.6%), were employed (91.8%), unmarried (59.2%), and MSM (49%). A total of 91.8% had active pulmonary TB, and 65.3% received the RHZE OAT regimen. Mean CD4⁺ counts increased from 104.24 cells/mm³ before therapy to 248.80 cells/mm³ at 6 months and 324.78 cells/mm³ at 12 months of ARV therapy (p < 0.001). Correlation analysis showed strong relationships across measurement periods (CD4⁺ pre-ARV–6 months: r = 0.663; CD4⁺ pre-ARV–12 months: r = 0.580; CD4⁺ 6–12 months: r = 0.763; p < 0.001). Conclusions: ARV therapy duration was positively and significantly associated with increased CD4⁺ counts in PLWHA with pulmonary TB coinfection, confirming ARV effectiveness in improving CD4⁺ levels and emphasising the importance of regular patient monitoring.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Additional Information: | [No. Panggil: 2210211128] [Pembimbing 1 : Erna Harfiani] [Pembimbing 2 : Pritha Maya Savitri] [Penguji : Hany Yusmaini] |
| Uncontrolled Keywords: | Antiretroviral, CD4⁺, Coinfection, PLWHA, Pulmonary Tuberculosis. |
| Subjects: | R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Fakultas Kedokteran |
| Depositing User: | JESSICA VALENTINA UMAR |
| Date Deposited: | 06 May 2026 08:54 |
| Last Modified: | 06 May 2026 08:54 |
| URI: | http://repository.upnvj.ac.id/id/eprint/50175 |
Actions (login required)
 |
View Item |